由于资金限制、临床高成本和流失率高、监管不确定性、对治疗安全性和有效性难以动摇的疑虑以及普遍对指导该领域研究的基础生物学缺乏了解，让突破性癌症免疫疗法的商业化越来越具有挑战性。但在我们制定 2025 年会议议程时，我们惊讶地发现，尽管面临这些挑战，人们仍然强烈希望寻找治疗实体肿瘤的有效方法。第 13 届 Immuno-Oncology Summit 将展示基于对生物学深刻理解的临床前和临床试验成功案例。内容涵盖了实体瘤领域的创新，包括双特异性/多特异性抗体、抗体-药物偶联物 （ADC）、同种异体和体内 CAR-T、TIL、TCR、Treg、多细胞治疗合作、肿瘤微环境、先天免疫、γ-δ T 细胞、NK 细胞、类器官建模、数据科学和机器学习。该计划还将自体免疫作为一个重要且互补的重点领域进行探索。
2025年的全体会议主题演讲者
Off-the-Shelf Allogeneic CAR T Therapy in the Treatment of Severe Autoimmune Diseases
Biao Zheng, PhD
CEO, BRL Medicine
PANEL DISCUSSION: Advancing Immunotherapy: Strategies for Preventing Attrition
Moderator:
Rakesh Dixit, PhD, DABT
President & Founder, Bionavigen Oncology, LLC and Regio Biosciences
Carter Caldwell, MBA
Co-Investment Program Director, University of Pennsylvania
Karen Chagin, MD
Senior Vice President, Early Stage Development, Adaptimmune
Margery Ma, PhD
Principal Consultant, NonClinical Regulatory Affairs, Eliquent Life Sciences
David Sommerhalder, MD
Clinical Investigator, Oncology, NEXT Oncology
PANEL DISCUSSION: Accelerating IO through Target Discovery
Moderator:
Tatiana Novobrantseva, PhD
CSO, NextPoint Therapeutics
Vitalay Fomin, PhD
Co-Founder, Numenos AI
Shameer Khader, PhD
Executive Director, Global Head of Data Science, Data Engineering and Computational Biology, Sanofi
Kristen Meerbrey, PhD
Director of Target Discovery, Therapeutic Innovation Center, Baylor College of Medicine
感谢我们 2025 年的赞助商
Corporate Support Sponsors:
